Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease

Gariani, Karim; Ryu, Dongryeol; Menzies, Keir J; Yi, Hyon-Seung; Stein, Sokrates; Zhang, Hongbo; Perino, Alessia; Lemos, Vera; Katsyuba, Elena; Jha, Pooja; Vijgen, Sandrine Elisabeth V; Rubbia-Brandt, Laura; Kim, Yong Kyung; Kim, Jung Tae; Kim, Koon Soon; Shong, Minho; Schoonjans, Kristina; Auwerx, Johan

doi:10.1016/j.jhep.2016.08.024

Scientific article

English

Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease

ContributorsGariani, Karim; Ryu, Dongryeol; Menzies, Keir J; Yi, Hyon-Seung; Stein, Sokrates; Zhang, Hongbo; Perino, Alessia; Lemos, Vera; Katsyuba, Elena; Jha, Pooja; Vijgen, Sandrine Elisabeth V; Rubbia-Brandt, Laura; Kim, Yong Kyung; Kim, Jung Tae; Kim, Koon Soon; Shong, Minho; Schoonjans, Kristina; Auwerx, Johan

Published inJournal of hepatology, vol. 66, no. 1, p. 132-141

Publication date2017

Abstract

To date, no pharmacological therapy has been approved for non-alcoholic fatty liver disease (NAFLD). The aim of the present study was to evaluate the therapeutic potential of poly ADP-ribose polymerase (PARP) inhibitors in mouse models of NAFLD.

Affiliation entities

Faculté de médecine / Section de médecine fondamentale / Département de pathologie et immunologie

Research groups

Métastases du foie (657)

Citation (ISO format)

GARIANI, Karim et al. Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease. In: Journal of hepatology, 2017, vol. 66, n° 1, p. 132–141. doi: 10.1016/j.jhep.2016.08.024

Article (Published version)

Identifiers

PID : unige:89086
DOI : 10.1016/j.jhep.2016.08.024
PMID : 27663419

Journal ISSN0168-8278

671views

521downloads

Creation24/10/2016 15:46:00

First validation24/10/2016 15:46:00

Update15/03/2023 00:57:16

Status update15/03/2023 00:57:15

Last indexation31/10/2024 05:06:06

Archive ouverte UNIGE

Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease

To date, no pharmacological therapy has been approved for non-alcoholic fatty liver disease (NAFLD). The aim of the present study was to evaluate the therapeutic potential of poly ADP-ribose polymerase (PARP) inhibitors in mouse models of NAFLD.

Technical informations